Better Health. Better Life.

Scientific Publication Highlights - trimtec-logo

Parameter Selection and Stimulating Effects of an Adjustable Gastric Electrical Stimulator in Dogs
Guo X, Li Y, Yao S, Chen S, Du Y, Wang Z.
(2014). Parameter selection and stimulating effects of an adjustable gastric electrical stimulator in dogs. Obesity surgery, 24(1), 78-84.

Gastric electrical stimulation for the treatment of obesity: from entrainment to bezoars-a functional review
Mintchev MP
(2013). Gastric electrical stimulation for the treatment of obesity: from entrainment to bezoars—a functional review. ISRN gastroenterology, 2013.

Design, implementation and testing of an implantable impedance-based feedback-controlled neural gastric stimulator
Arriagada AJ, Jurkov AS, Neshev E, Muench G, Andrews CN, Mintchev MP
(2011). Design, implementation and testing of an implantable impedance-based feedback-controlled neural gastric stimulator. Physiological measurement, 32(8), 1103.

Comparative gastric motility study of Enterra™ Therapy and neural gastric electrical stimulation in an acute canine model
Arriagada A, Jurkov AS, Neshev E, Muench G, Mintchev MP, Andrews CN.
(2011). Comparative gastric motility study of EnterraTM Therapy and neural gastric electrical stimulation in an acute canine model. Neurogastroenterology & Motility,
23(3), 271-e122.

Implantable functional gastrointestinal neurostimulation
Jurkov AS, Arriagada A, Mintchev MP
Conf Proc IEEE Eng Med Biol Soc. 2009; 2009:4615-8. doi: 10.1109/IEMBS.2009.5332682.
 
Pilot acute study of feedback-controlled retrograde peristalsis invoked by neural gastric electrical stimulation
Aelen P, Jurkov A, Aulanier A, Mintchev MP
Physiol Meas. 2009 Mar; 30(3):309-22. doi: 10.1088/0967-3334/30/3/006.
 
Feedback control of retrograde peristalsis using Neural Gastric Electrical Stimulation
Aelen P, Aulanier AL, Mintchev MP
Conf Proc IEEE Eng Med Biol Soc. 2008; 2008:3375-80. doi: 10.1109/IEMBS.2008.4649930.
 
Manipulation of food intake and weight dynamics using retrograde neural gastric electrical stimulation in a chronic canine model
Aelen P, Neshev E, Cholette M, Crisanti K, Mitchell P, Debru E, Church N, Mintchev MP
Eurogastroenterol Motil. 2008 Apr;20(4):358-68. Epub 2007 Nov 20.
 
Parametric study of neural gastric electrical stimulation in acute canine models
Onen D, Jalilian E, Neshev E, Mintchev MP
(IEEE Trans Biomed Eng. 2007 Mar;54(3):429-35.
 
Neural gastrointestinal electrical stimulation enhances colonic motility in a chronic canine model of delayed colonic transit
Sanmiguel CP, Casillas S, Senagore A, Mintchev MP, Soffer EE
Neurogastroenterol Motil. 2006 Aug;18(8):647-53.
 
Implantable neural electrical stimulator for external control of gastrointestinal motility
Jalilian E, Onen D, Neshev E, Mintchev MP
Med Eng Phys. 2007 Mar;29(2):238-52. Epub 2006 May 3.
 
Pre-pyloric neural electrical stimulation produces cholinergically-mediated reverse peristalsis in the acute canine model of microprocessor-invoked gastric motility for the treatment of obesity
Neshev E, Onen D, Jalilian E, Mintchev MP
Gut. 2002 Apr;50(4):475-9.
 
Microprocessor controlled movement of solid colonic content using sequential neural electrical stimulation
Amaris MA, Rashev PZ, Mintchev MP, Bowes KL
Gut. 2002 Apr;50(4):475-9.
 
Microprocessor-controlled movement of solid gastric content using sequential neural electrical stimulation
Mintchev MP, Sanmiguel CP, Amaris M, Bowes KL
Gastroenterology. 2000 Feb;118(2):258-63.
 
Microprocessor controlled movement of liquid gastric content using sequential neural electrical stimulation
Mintchev MP, C Sanmiguel, S Otto, and K Bowes
Gut. 1998 Nov; 43(5): 607–611. PMCID: PMC1727304.

 

Drug Treatment Portfolio

Obesity, Weight Management Treatment

C-103 is a novel reformulation of orlistat, patented until 2030 in the U.S.  Orlistat is FDA-approved for weight management and sold by Roche as Xenical® (prescription) and by GlaxoSmithKline as alli® (over-the-counter).  Proven safe and effective in over 100 clinical trials, orlistat is the best-selling weight loss medication of all time with peak sales over $900 million in 2007.  The C-103 reformulation addresses adverse events reported by over 90% of orlistat users. These adverse events have led to the decline in Orlistat sales to approximately $200 million in recent years. 

C-103 is intended to maintain the efficacy of orlistat while minimizing its socially unacceptable adverse events. Unlike other weight loss drugs:

  • Orlistat is not an amphetamine
  • Orlistat does not affect the central nervous system
  • Orlistat is not systemically absorbed
  • Orlistat is the only FDA-approved OTC weight loss drug because of its safety
  • Orlistat is the only FDA-approved weight loss drug for adolescent patients (age 12-18)

Infertility Treatment

ToConceive is an innovative new infertility treatment that offers hope and assistance to the millions of couples worldwide struggling to start a family. Our product is an easy to use topical gel that helps to balance the pH of the vagina and is clinically proven to increases a women’s natural production of transudate (sexual lubrication). This increase in natural transudate is required for successful “Sperm Capacitation” to occur. Without the process of Sperm Capacitation, the sperm would not have the ability to travel the required distance to the ovum or have the appropriate chemical makeup for successful conception to occur.

ToConceive is a women’s health treatment supported by a FDA 510K clearance and is protected by four USPTO patents. ToConceive’s proven ability to increase a woman’s natural production of transudate results in significantly higher success rates for couples trying to conceive, without the added expense, or stress, associated with assisted reproduction treatments.